TrkB transmembrane domain: bridging structural understanding with therapeutic strategy

Trends Biochem Sci. 2024 May;49(5):445-456. doi: 10.1016/j.tibs.2024.02.001. Epub 2024 Mar 2.

Abstract

TrkB (neuronal receptor tyrosine kinase-2, NTRK2) is the receptor for brain-derived neurotrophic factor (BDNF) and is a critical regulator of activity-dependent neuronal plasticity. The past few years have witnessed an increasing understanding of the structure and function of TrkB, including its transmembrane domain (TMD). TrkB interacts with membrane cholesterol, which bidirectionally regulates TrkB signaling. Additionally, TrkB has recently been recognized as a binding target of antidepressant drugs. A variety of different antidepressants, including typical and rapid-acting antidepressants, as well as psychedelic compounds, act as allosteric potentiators of BDNF signaling through TrkB. This suggests that TrkB is the common target of different antidepressant compounds. Although more research is needed, current knowledge suggests that TrkB is a promising target for further drug development.

Keywords: allosteric modulators; antidepressant drugs; cholesterol; neuroplasticity; neurotrophic factors; psychedelics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antidepressive Agents / chemistry
  • Antidepressive Agents / metabolism
  • Antidepressive Agents / pharmacology
  • Antidepressive Agents / therapeutic use
  • Brain-Derived Neurotrophic Factor / chemistry
  • Brain-Derived Neurotrophic Factor / metabolism
  • Humans
  • Membrane Glycoproteins*
  • Protein Domains
  • Receptor, trkB* / chemistry
  • Receptor, trkB* / metabolism
  • Signal Transduction

Substances

  • Receptor, trkB
  • Antidepressive Agents
  • Brain-Derived Neurotrophic Factor
  • tropomyosin-related kinase-B, human
  • Membrane Glycoproteins